Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-2: Neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy plus adjuvant gemcitabine in resectable or borderline resectable pancreatic cancer
2024-516260-29-00Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, folinic acid, oxaliplatin, fluorouracil and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus MC. Primary endpoint: overall survival. Started Oct 2024; status: completed.
02
Drugs
irinotecanfolinic acidoxaliplatinfluorouracilgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516260-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516260-29-00.